Price Chart

Profile

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
URL https://www.ionispharma.com
Investor Relations URL https://ir.ionispharma.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
URL https://www.ionispharma.com
Investor Relations URL https://ir.ionispharma.com
HQ State/Province California
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 21, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A